An open-label study of rabeprazole in patients with Zollinger?Ellison syndrome or idiopathic gastric acid hypersecretion
- Resource Type
- Authors
- T. Bjaaland; A. Morocutti; M. Merrouche; M. Mignon; T. J. Humphries
- Source
- Alimentary Pharmacology and Therapeutics. 24:1439-1444
- Subject
- Adult
Male
medicine.medical_specialty
medicine.drug_class
Rabeprazole
Lansoprazole
Proton-pump inhibitor
Gastroenterology
2-Pyridinylmethylsulfinylbenzimidazoles
Gastric Acid
Zollinger-Ellison Syndrome
Basal (phylogenetics)
Internal medicine
medicine
Humans
Pharmacology (medical)
Enzyme Inhibitors
Omeprazole
Aged
Gastrinoma
Hepatology
business.industry
Middle Aged
medicine.disease
digestive system diseases
Zollinger-Ellison syndrome
Endocrinology
Gastric acid
Female
Antacids
business
medicine.drug
- Language
- ISSN
- 1365-2036
0269-2813
SUMMARY Background Omeprazole and lansoprazole are both of proven efficacy in the treatment of Zollinger‐Ellison syndrome and idiopathic gastric acid hypersecretion. Rabeprazole, which has a similar mechanism of action, has not previously been studied in these diseases. Aim To determine the dose of rabeprazole that decreased basal acid output to safe levels in patients with Zollinger‐Ellison syndrome or idiopathic gastric acid hypersecretion. Methods Patients with Zollinger‐Ellison syndrome or idiopathic gastric acid hypersecretion were given rabeprazole 60 mg once daily for uncomplicated disease or 40 mg twice daily for complicated disease. Doses were titrated according to response and continued for 2 years. Efficacy was assessed primarily by measuring basal acid output. Results All patients had basal acid output before the next dose controlled to